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Abstract
Background: Initially known as the reproductive hormone, relaxin was shown to possess other therapeutically
useful properties that include extracellular matrix remodeling, anti-inflammatory, anti-ischemic and angiogenic
effects. All these findings make relaxin a potential drug for diverse medical applications. Its precursor, pro-relaxin, is
an 18 kDa protein, that shows activity in in vitro assays. Since extraction of relaxin from animal tissues raises several
issues, prokaryotes and eukaryotes were both used as expression systems for recombinant relaxin production. Most
productive results were obtained when using Escherichia coli as a host for human relaxin expression. However, in
such host, relaxin precipitated in the form of inclusion bodies and, therefore, required several expensive recovery
steps as cell lysis, refolding and reduction.
Results: To overcome the issues related to prokaryotic expression here we report the production and purification
of secreted human pro-relaxin H2 by using the methylotrophic yeast Pichia pastoris as expression host. The methanol
inducible promoter AOX1 was used to drive expression of the native and histidine tagged forms of pro-relaxin H2 in
dual phase fed-batch experiments on the 22 L scale. Both protein forms presented the correct structure, as determined
by mass spectrometry and western blotting analyses, and demonstrated to be biologically active in immune enzymatic
assays. The presence of the tag allowed to simplify pro-relaxin purification obtaining higher purity.
Conclusions: This work presents a strategy for microbial production of recombinant human pro-relaxin H2
in Pichia pastoris that allowed the obtainment of biologically active pro-hormone, with a final concentration
in the fermentation broth ranging between 10 and 14 mg/L of product, as determined by densitometric
analyses.
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Background
Relaxin is a multifunctional peptide hormone initially
identified in reproductive tissues during pregnancy and
later classified as a pleiotropic factor that induces bio-
chemical changes also in a number of non-reproductive
organs. Indeed, relaxin receptors have also been found
in brain, heart, skin, small intestine and blood vessels
[1]. Three relaxin genes are present in the human
genome and they code for the peptides indicated as H1,
H2 and H3, which differ in their primary and tertiary
structure, activity and expression site. H2, is the major
circulating form and it is mainly produced in the corpus
luteum [2]. Besides its well-established biological role
during pregnancy in reproductive tissues, where it re-
laxes the pelvic ligaments and tendons, more recently
relaxin has been shown to be involved in the maternal
adaptation of the renal and cardiovascular systems.
Moreover, the latest studies have also established the po-
tential of relaxin as vasodilator, and its contribution in
angiogenesis and extracellular-matrix remodeling [3–7].
Most of these functions are important in the underlying
pathology of acute heart failure (AHF), in fact, cardio-
renal protective effects along with a significant benefit of
dyspnea relief in patients with this pathology seem to be
attributable to the capacity of relaxin to improve sys-
temic, cardiac and renal hemodynamics, and protect
cells and organs from damage via its neuro-hormonal,
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anti-inflammatory, anti-remodeling, anti-fibrotic, anti-
ischemic, and pro-angiogenic effects [3, 8]. In 2012 sere-
laxin, recombinant human relaxin, passed Phase III clin-
ical trials for the treatment of AHF [9] and was
appointed as “Breakthrough Therapy” by the US Food
and Drug Administration [8]. Furthermore, by using an
in vivo mouse model Hampel and colleagues found a
novel role for Relaxin 2 for the maintenance and regen-
eration of the ocular epithelial cell layer, underlying a
new potential therapeutic application in ophthalmology
for the treatment of corneal ulcerations [6].
Differently from other peptide hormones belonging to
the same family, such as pro-insulin, it was demon-
strated that also the immature/unprocessed hormone
pro-form, pro-relaxin, is biologically active [10, 11]. Al-
though animal tissues represent a source of relaxin,
their pro-relaxin content is very low. Moreover, extrac-
tion procedures are inefficient. About 0.03 mg of re-
laxin and 0.8 mg of pro-relaxin were obtained by using
165 g of placenta homogenate extracts from 40 ham-
sters [12] and a yield of 0.72 mg of pro-relaxin per
gram of wet tissue was obtained from decapsulated cor-
pus luteum of pregnant gilts [13]. In addition the rela-
tively low structure similarity between animal derived
H2 forms and human ones (eg. only share 55% identity)
might elicit strong immunogenic responses thus redu-
cing the field of application. Therefore, it is desirable to
replace such animal-tissue extraction procedures with
biotechnological processes, in order to generate larger
and safer stocks of relaxin/pro-relaxin for therapeutic
applications. The production of human relaxin/pro-re-
laxin by intensive cultures of genetically engineered
microorganisms is more compatible with pharmaceutical
applications. To date, different prokaryotic and eukaryotic
hosts have been adopted to produce recombinant relaxin
and pro-relaxin all sharing the same limitation repre-
sented by quite low expression levels [10, 11, 13–16].
However, human recombinant relaxin H2 was expressed
in E.coli cells, purified from inclusion bodies and charac-
terized, demonstrating biologically active in in vitro assays
with human endometrial cells [17], and recently reached
phase III clinical trials for patients with acute decompen-
sated heart failure.
The theoretical possibility of secreting high levels of
correctly folded human proteins in the yeast P. pastoris,
and the availability of commercial protease-deficient
strains that reduce protein degradation over time, en-
couraged our efforts towards the use of this yeast as host
for the production of human pro-relaxin H2.
In the present work a simple approach was established
for the production of recombinant human pro-relaxin H2
on a semi-defined medium exploiting glycerol/methanol
fed-batch fermentations that result in the production of
active pro-hormone as established by bioactivity assays.
Results
Strategy and construction of the recombinant strains
Since one of the main problems related to protein pro-
duction and purification processes is degradation by
endogenous proteases, the production of human pro-
relaxin H2 was evaluated in a commercial Pichia knock-
out strain that produces a lower number of vacuolar
proteases. The aminoacid and the codon-optimized
nucleotide sequences of the native and histidine tagged
human pro-relaxin H2 used in this study are shown in
Additional file 1. The pro-relaxin sequences with and
without histidine tag were cloned in the pPink vector
(Invitrogen) in frame with the Mat-α signal sequence to
enable protein secretion. The histidine tag was fused to
the C-terminus of the protein in order to compare dif-
ferent purification strategies. All constructs were se-
quence verified before integration into the genome of
competent Pichia pink cells. The colonies that showed a
change in color from pink to white were further ana-
lyzed, confirming the specific insertion of the pro-
relaxin gene into their genome and generating the
recombinant strains indicated in the following as Pichia
pink-prel and Pichia pink-prelHis, respectively.
Shakeflask and fermentation experiments
Eight positive colonies for each recombinant strain were
screened in shakeflasks for pro-relaxin productivity by
methanol induction. The supernatants of all clones
collected after 72 h of methanol induction were concen-
trated and analyzed by western blotting. All colonies
showed a band of the expected molecular weight. The
colonies producing most intense bands were selected for
further experiments (data not shown).
Pichia pink-prel and Pichia pink-prelHis were grown
in fed-batch cultures involving initial batch and DO-stat
growth on glycerol to increase biomass, followed by a
switch to a methanol fed-batch phase to induce protein
expression. After the batch phase about 300 g of total
glycerol were fed to the cultures until a concentration of
about 30 gcdw/L of biomass was reached. The following
addition of 300 g of methanol, with a volumetric flow
that ranged between 1 and 2 g/L∙h during 24 h of induc-
tion, only slightly improved the final biomass titer. Ac-
cumulation of methanol (3-6 g/L) was observed in both
strains 2-3 h after induction indicating a lower initial
consumption rate. This also corresponded to a slight
decrease of biomass production in the first hours post-
induction. On average a 15% higher concentration of
biomass was obtained at the end of the process for
Pichia pink-prel (Fig. 1).
Samples for pro-relaxin analyses by western blotting
were taken during the process for both strains, as
described in the methods section. Western blotting ex-
periments with anti-prorel and anti-rel antibodies on
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cell-free supernatant and cell lysates were performed for
both strains at time zero, 4, 8 and 24 h after induction
demonstrating different protein patterns in the two
strains (Fig. 2). The time zero sample was taken when
cells were growing in fed-batch on limiting amounts of
glycerol, prior to the addition of methanol. Densitometric
analyses of the films indicated an average concentration
of 10 and 14 mg/L of pro-relaxin in the fermentation
broth 24 h post induction in Pichia pink-prel and
Pichia pink-prelHis, respectively. For both strains the
portion of intracellular protein was on average only 1-
2% of the total produced.
Purification of pro-relaxin
Two different protocols were used for the purification
of pro-relaxin from the two recombinant strains
(Fig. 3). The first attempt to purify human pro-relaxin
H2 from Pichia pink-prel was a combination of ultra-
filtration and chromatography (ion exchange and re-
verse phase). The cell free supernatant was initially
ultra-filtered on 3 kDa membranes in order to con-
centrate the sample and then it was loaded on anion
exchange column. This step was only useful to par-
tially purify the sample, in fact, separation in the elu-
tion phase was not efficient and besides the unbound
fraction only one single undefined peak was obtained.
The latter was loaded on a RPC column following a
gradient step elution, and the recovered fractions
were analysed by western blotting (Fig. 4a). The peak
eluted with 35% of eluent B corresponds to pro-
relaxin and in accordance with IEX results its repre-
sentativity is quite low. The peak was recovered and
analysed by HPLC showing an elution time of about
52.5 min in the set conditions. The samples showing
Fig. 1 Dual phase fed-batch experiments. Time course of glycerol and methanol consumption, and biomass production during the processes.
Native indicates parameters relative to the fermentation of the strain Pichia pink-prel that produces un-tagged pro-relaxin, whereas tagged refers
to strain Pichia pink-prelHis producing His tagged pro-relaxin. Fermentation experiments were run in triplicate for each strain and the reported
data are the mean values ± S.D
Fig. 2 Determination of intracellular and extracellular relaxin and
pro-relaxin distribution. Western blotting with anti-prorelaxin anti-relaxin
antibodies on intracellular and extracellular fractions collected at
different time points during fermentation experiments performed
with recombinant strains Pichia pink-prel (a) and Pichia pink-prelHis (b)
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a higher representativeness than 60% were analyzed
by mass spectrometry.
The purification of the His tagged pro-relaxin obtained
from the fermentation of Pichia pink-prelHis did not in-
volve any membrane based step. The fermentation broth
was centrifuged and the supernatant was incubated with
a Ni FF sepharose resin in batch, in order to attach
tagged pro-relaxin. After imidazole separation the
sample was loaded on a RPC column that showed the
presence of different peaks demonstrating a low repre-
sentativeness of pro-relaxin (Fig. 4b). As confirmed by
western blotting experiments pro-relaxin was only
present in the fraction eluted with 30% eluent B, indicat-
ing a modification of the interaction of tagged pro-relaxin
with the matrix (Fig. 4b). The fraction demonstrating
the presence of pro-relaxin was analysed by HPLC
and, as previously observed during FPLC purifcation,
elution time in these conditions was slightly different,
in fact, tagged pro-relaxin was eluted after 56.1 min,
probably due to the presence of the His tag and of
the Xa factor cleavage site. The pro-relaxin peak area
shows a representativeness that is higher compared to
that obtained with the recombinant native form,
reaching 80% purity.
The purified fractions of both un-tagged and tagged
pro-relaxins were analysed by RP-HPLC/ESI-IT-TOF.
Figures 5a and b show the analytical chromatogram of
the native and tagged pro-relaxins, respectively. Inspec-
tion of the two chromatograms clearly shows the differ-
ent quality of the two purified samples. In the first
chromatogram, a broad main peak at Rt 9.83 min (53%
of acetonitrile - 0.05% TFA) is clearly evident, while the
second chromatogram shows a more intense and
sharper peak at Rt 10.41 min (57% of acetonitrile 0.05%
Fig. 3 Schematic overview of downstream processes. Initial step used
to recover the supernatant from all dual-phase fed-batch fermentation
broths (a) followed by different strategies used for the purification of
pro-relaxin (b) and His tagged pro-relaxin (c)
Fig. 4 FPLC and Western blot analyses of partially purified recombinant un-tagged and tagged prorelaxin. (a) Human recombinant pro-relaxin H2
was purified from fermentation supernatant by ultrafiltration, IEX and RPC. The panel shows the RP chromatogram; the recovered fractions were
analysed by western blotting. Lane 1) Unbound, lane 2) 20% B, lane 3) 30% B, lane 4) 35% B, M) molecular weight marker. (b) Human recombinant His
tagged pro-relaxin H2 was recovered by affinity chromatography in batch and sequentially the sample was loaded on a RPC column; the
resulting chromatogram is shown in the panel. The fractions recovered from RPC were analysed by western blotting. Lane 1) Unbound,
lane 2) 20% B, Lane 3) 30% B, Lane 4) 35% B, M) molecular weight marker. The arrow in the RP chromatograms indicates the peaks
recognized by the anti pro-relaxin antibody
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TFA), thus evidencing the higher purity of the tagged
pro-relaxin.
The mass spectra of the two samples display several
signals indicative of high molecular weight species; how-
ever, they were not easily assignable, due to low signal/
noise ratio, caused by inefficient ionization of the intact
proteins. Therefore, the tagged pro-relaxin, which dem-
onstrated to be the purest sample, was identified by
standard proteomic procedures. LC–MS/MS of the
tryptic digest and database search in the human subset
of NCBI with online available MASCOT software
allowed us to confirm the presence of the intact tagged
pro-relaxin. In fact, eight peptides were identified, cover-
ing 38% of expressed sequence and, most notably, com-
prising the N- and C-terminal portions (see Fig. 5c).
Given the different glycosylation pattern between human
and yeast, MS spectra of the identified peptides were
checked for O-glycosylation. Post-translational modifica-
tions were absent in the seven peptides containing Ser/
Thr residues (out of the eight identified). These analyzed
peptides contain 50% of the Ser/Thr residues present in
the whole sequence.
EIA immunoassay
cAMP levels in the fermentation samples and in the
fractions collected after the last purification step were
determined by cAMP biotrak EIA assay. The cAMP
response of the THP-1 cells were used to test the bio-
logical activity of pro-relaxin produced from engineered
Pichia strains. All fractions of tagged and untagged pro-
relaxin resulted active when compared to human relaxin
used as control; however, while the supernatant recov-
ered 24 h post induction showed a similar activity in
both recombinant strains, samples deriving from the
final steps of the purification processes demonstrated
a different activity. In particular, a significantly higher
(p < 0.05) activity was found for the His-tagged pro-
relaxin, as compared to the native form (Fig. 6).
Discussion
Relaxin is a natural hormone with several potential
applications the use of which is partly limited by the in-
sufficient and hazardous animal derived protein supply.
For this reason numerous attempts to develop a biotech-
nological process for relaxin production in prokaryotic
and eukaryotic hosts were previously evaluated. Porcine
pro-relaxin was also expressed in transgenic tobacco
[18]. In vitro studies demonstrate that porcine relaxin
may possess various therapeutic effects, and tobacco was
selected because it is a non-food, non-feed crop, and re-
combinant protein production could readily be scaled
up. The authors verified the occurred insertion, tran-
scription and translation of the gene of interest but no
concentration or purity data were reported [18]. Also
immortalized bovine mammary epithelial (MAC-T) cells
were used as hosts for the production of a recombinant
tagged equine pro-relaxin by Neumann and colleagues
[16]. Cells were transfected with the pST-eRLX con-
struct by using a liposome-mediated method. The con-
centration of relaxin found in the supernatants was of
0.59 ± 0.22 mg/L while sample lysates showed a concen-
tration of 0.37 ± 0.22 mg/L. The use of MAC-T cells as
expression hosts offers the advantage of producing well
folded proteins with a correct glycosylation pattern,
however, some issues concern process scale-up and the
complexity of the medium to be used. E.coli was used as
Fig. 5 LC-MS/MS analysis of recombinant pro-relaxins. (a) RP-HPLC chromatogram with UV detection at 210 and 280 nm of untagged pro-relaxin.
(b) RP-HPLC chromatogram with UV detection at 210 and 280 nm of tagged pro-relaxin. (c) Tryptic digested peptides and sequence covered of
tagged pro-relaxin, as assessed by MASCOT and manual analysis of MS/MS data
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host for the expression of both porcine pro-relaxin H2
and of human recombinant relaxin H2 [15, 17]. How-
ever, since the proteins were expressed as inclusion
body, cell lysis and in vitro renaturation were necessary
for protein recovery, thereby making the process expen-
sive and not competitive for production scale up. Never-
theless, recombinant human relaxin H2 was the only
one that reached phase III clinical trials for patients with
acute decompensated heart failure [19].
The aim of the present work was to produce the unpro-
cessed form of this hormone, pro-relaxin, that was shown
to posses activity before processing, as well [10, 11]. We
chose the metylotrophic yeast P. pastoris as expression
host, since yeasts combine the capability of a protein pro-
cessing apparatus, that is typical for eukaryotic organisms,
to the absence of endotoxins and viral DNA. The human
pro-relaxin H2 gene, with and without a C-terminal tag of
histidines, was introduced in the genome of a protease de-
leted strain (Invitrogen, Carlsbad, CA) under the control
of the AOX1 methanol-inducible promoter and in frame
with a secretion signal, resulting in strains Pichia pink-
prelHis and Pichia pink-prel, respectively. Fed-batch
processes based on a dual phase growth on glycerol and
methanol were performed on 22 L fermenters resulting in
a final yield of about 35 gcdw/L of biomass. One of the
main problems commonly encountered during recombin-
ant protein production is protein loss due to protease deg-
radation. We therefore modified the protocol suggested
by Pai-Chanfrau and collegues [20] that evaluated the ef-
fect of temperature, pH and addition of excess nitrogen
source and EDTA, on mini-pro-insulin expression. It was
also previously observed that addition of casaminaocids
reduced proteolysis of ovin interferon in P. pastoris by
acting as preferential substrates [21]. We used a medium
containing casein hydrolysate as main N source, and, be-
fore methanol induction, one single pulse of EDTA and
ammonium sulphate was performed to divert proteases
activity. The behavior of the recombinant strains was quite
similar in terms of final biomass, growth rate and C-
source consumption rate. Although Pichia is one of the
hosts that is most commonly used for protein secretion
several studies aim to improve the secretion of foreign
proteins due to the variability of efficiency [22, 23]. In
both strains 1-2% of pro-relaxin could also be found inside
the cells indicating a partial, although almost negligible,
failure of the secretion system. Expression of secreted
tagged pro-relaxin strongly increased during induction
whereas it remained constant inside the cell. Moreover
the processed form of the pro-hormone (relaxin) was de-
tected in both strains in the extracellular fraction. One of
the key steps involved in secretion and activation of pep-
tide hormones is site specific proteolysis, which is medi-
ated in eukaryotic cells by serine proteases. In yeast the
Kex2 enzyme is undertaking this role. It was previously
demonstrated that Kex2 mainly targets proteins that are
secreted to the environment [24] and coexpression of hu-
man pro-relaxin with Kex2 from Saccharomyces cerevisiae
in human kidney cells resulted in the secretion of mature
relaxin [25]. It was therefore not surprising to observe re-
laxin in the extracellular fraction of broth samples. The
result is a potentially more powerful active principle
composed of a mixed population of pro-relaxin, that
should have a higher half life and therefore a better
pharmacokinetic performance, and relaxin, for immedi-
ate applications. Western blot densitometric analyses
performed on the supernatants and cell lysates showed
quite similar concentrations of native and tagged pro-
relaxin at the end of the fermentation process, that
ranged between about 10 and 14 mg/L, respectively.
Different procedures were used for the purification of
the native and tagged forms of pro-relaxin produced.
However, one of the major issues encountered during
downstream processing was protein degradation. The
output of the computational analysis of the human pro-
insulin aminoacidic sequence with the ProtParam tool
[26] indicates an instability index of 37.52 and classifies
the protein as “stable”. The same analysis performed on
pro-relaxin H2, that also belongs to the insulin-like
Fig. 6 Immunoenzymatic activity assays. Ability of human recombinant
pro-relaxin H2 to stimulate cAMP production in a relaxin receptor
expressing cell line (THP1) in comparison to the relaxin standard.
The tagged and native recombinant pro-forms of the hormone
were compared. 24 h P.I indicates that the test was performed on the
supernatant collected during the fermentation process; P.P. indicates
that the test was performed on prorelaxin samples recovered after
purification. Data are mean ± S.D. values of three independent
experiments. T-test results are indicated in the figure: *p < 0.05
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family of hormones, results, on the contrary, in an instabil-
ity index of 77.46 and classifies the protein as “unstable”.
Both purification strategies allowed the attainment of
proteins with the expected aminoacidic sequence and
that also demonstrate binding to the relaxin receptor
and therefore imply biological activity compared to the
human relaxin control. A comparison of the purification
efficiency and yield obtained during the two processes is
difficult to perform due to the absence of a method that
allows a precise determination of the concentration of
pro-relaxin in the fermentation broth and after each
purification step. The first strategy used for native pro-
relaxin purification, based on a sequence of UF, IEX and
RPC chromatography resulted in a protein with a final
purity of 60% as determined by HPLC. The difficulties
found during the purification procedure addressed us to-
wards the development of a second strategy focused on
the addition of a 6xHis-tag in order to (i) reduce protein
losses due to the interaction with UF membranes (ii)
minimize degradation by reducing process time (iii) per-
form most steps at low temperature in controlled condi-
tions. The tag was added at the C-terminus of human
pro-relaxin. Moreover a Xa factor cleavage site was
inserted after the tag to allow removal of the latter after
the purification step. The C-terminus was chosen, based
on the work that investigated on the geometry of the re-
laxin receptor binding site, according to which addition
to the C-terminus would not interfere with residues de-
fined as critical for receptor binding, on the B chain
interface [27]. This approach resulted in a final sample
purity of up to 80%.
The higher content of intact pro-relaxin in the tagged
sample was confirmed by LC-MS analyses. In fact, the
RP-HPLC profiles clearly indicate the higher recovery
and purity of the tagged purified fractions. This allowed
a complete proteomic analysis of the tryptic digest, con-
firming the intact sequence of the tagged recombinant
protein. Thus, LC-MS/MS analysis with IT-TOF plat-
form revealed a valuable tool for rapid and sensitive
analyses, which can be used in combination with bio-
chemical methodologies, in order to confirm the purity
and the chemical structure even in complex samples,
with the ultimate purpose of explaining differences in
functional properties [28, 29]. Our spectra analyses also
excluded any post-translational modification. This is
particularly meaningful, since hypermannosylation is a
known issue in yeast expression. In fact, hypermannosy-
lated proteins may imply drawbacks, such as allergic
reactions, thus limiting their therapeutic use [30, 31].
Conclusions
With the aim of developing an alternative to currently
used extraction procedures from animal tissues and pos-
sibly prokaryotic relaxin production avoiding recovery
from inclusion bodies, the present study demonstrates the
possibility of producing biologically active human pro-
relaxin and relaxin by exploiting the yeast P. pastoris. The
purified recombinant proteins underwent a complete
proteomic analysis confirming their intact sequence with
a greater purity of the tagged protein. Optimization of the
fermentation strategy and of the purification process are
however necessary to improve biomass titers for pharma-
ceutical applications.
Methods
Materials
Genomic DNA and plasmid DNA were isolated using
Qiagen DNeasy kit and Qiagen miniprep kitt (Qiagen,
Valencia, CA) respectively according to the manufac-
turer’s instructions. Restriction endonuclease digestions,
DNA ligations, SDS-PAGE and agarose gel electrophor-
esis were performed using standard techniques [32].
LCMS ultragradient grade water, acetonitrile and formic
acid were supplied by Romil, Cambridge, UK. TFA was
purchased from Applied Biosystems (Carlsbad, Califor-
nia). Proteomic grade trypsin, dithiothreitol (DTT) and
iodoacetamide (IAA) were supplied by SIGMA.
Construction of Pichia pastoris expressing human pro-
relaxin H2
The sequence coding for human pro-relaxin isoform H2
was synthesized by MWG (Milan, Italy) and the codon
usage was optimized for expression in P. pastoris. The
optimized sequence is reported in additional file 1. The
gene was amplified with ProrlxUp:5’ –TCTTggATggAA-
gAggTgATcAA-3’ and either ProrlxDw: 5’ ggTACC
TTAACAAAACCTAgCAAggg 3’ or ProrlxHISDw: 5’ gg
TACC tta atgatgatgatgatgatgtctaccctcaat ACA AAA
CCT AgC AAg gg 3’ for the insertion of the C-terminal
histidine tag. Both reverse primers contain the KpnI rec-
ognition site for cloning into pPinkα-HC (Invitrogen,
Carlsbad, CA). This integration vector contains the
alpha mating pre-sequence necessary to guide protein
secretion and the methanol inducible promoter
AOX1. The recombinant vectors were sequenced by
BMR genomics (Padoa, Italy) to verify sequence ac-
curacy and in frame insertion of pro-relaxin with the
secretion sequence.
Transformation was performed according to Invitrogen
guidelines. The pPinkα-prorlxPp and pPinkα-prorlxhisPp
recombinant vectors were linearized with PmeI before
electroporation into Pichia pink strain 4 (Invitrogen,
Carlsbad, CA). The strain is a double knock-out for two
vacuolar proteases encoded by pep4 and prb1. Positive
clones were selected on adenine drop out medium, and
the presence of the pro-relaxin gene was further verified
by colony PCR.
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Shake flask experiments
Positive clones were screened by inoculating single col-
onies in 10 ml of BMGY medium containing glycerol
10 g/L, yeast extract 10 g/L, bactopeptone 20 g/L, potas-
sium phosphate buffer pH = 6.0 100 mM, biotin 0.0004%
p/v, yeast nitrogen base 1.34% p/v in 125 ml shake
flasks. Colonies were grown in agitation at 30 °C for
24 h. Cells were then collected by centrifugation and re-
suspended in BMMY that contains 0.5% v/v methanol
instead of glycerol to induce recombinant protein
expression. Pulses of 0.5% v/v of pure methanol were
performed after 24 h and 48 h for a total of 72 h of
induction. Supernatants were collected to verify and
compare the presence of the protein in the different
clones. The supernatants were concentrated and diafil-
tered on 50 and 3 KDa ultrafiltration membranes and
analysed by western blotting.
22-L fermentation experiments
Fermentation experiments were carried out in a Biostat C
reactor (Sartorius Stedim; Melsungen, Germany) with
initial working volume of 7 L. The medium used for all ex-
periments modified from [20] contained: 20 g/L glycerol,
10 g/L casein hydrolysate, 13.4 g/L YNB, 0.0004 g/L biotin
and 100 mM KH2PO4 K2HPO4 salts. Temperature was set
at 22 °C, pH was fixed at 6.3 via automated addition of
30% v/v NH4OH and 30% v/v H3PO4. The airflow was
kept constant at 1.4 vvm. The recombinant strains were
pre-cultured in shakeflasks at 22 °C for about 21 ± 1 h in
200 ml of medium. The culture was transferred to the
bioreactor and after approximately 24 ± 2 h the sharp in-
crease of the DO peak indicated the depletion of the initial
carbon source. The starting concentration of glycerol and
casein were restored by the addition of a concentrated
medium (280 g/L glycerol, 140 g/L casein) the consump-
tion of which was followed by a glycerol DO-stat phase
(PO2 set point 30%) for a total of about 43 ± 2 h. In order
to maintain an excess of nitrogen source before initiating
the methanol induction phase about 0.03 M EDTA and
0.26 M ammonium sulphate were also added. An expo-
nential feeding profile ranging from 1 to 1.4 g/L∙h of
methanol in the first 8 h after induction, and from 1.5 to
2 g/L∙h from 8 to 24 h post induction was set, and cultures
were stopped after 24 h.
For the duration of all cultivations broth samples
were withdrawn from the reactors at regular time
intervals for the determination of substrates and extra-
cellular metabolites.
Broth samples were also withdrawn pre-induction and
4, 8 and 24 h post-induction with methanol for western
blot analyses to compare the amount of intracellular and
secreted pro-relaxin over time.
Fermentation experiments were performed in triplicate
for each strain, and curves showing biomass production
and, glucose and methanol consumption are mean
values ± S.D. for each time point.
Downstream processes
The culture broth was centrifuged at the end of the fer-
mentation processes at 5000xg at 4 °C for 30 min (Avanti
J26 XP, Beckman CoulterTM) and the supernatant was re-
covered. Ten microliters/L of protease inhibitor (Complete
protease inhibitor, Roche) prepared by dissolving one table
in 10 mL of ultrapure water was immediately added to the
supernatant at a concentration of 100 μl/L. Figure 3 shows
the purification protocol used for tagged and untagged
pro-relaxin. The clarified supernatant was concentrated by
tangential flow filtration (TFF) on a Sartoflow alpha system
(Sartorius Stedim, Milan, Italy). The cell-free supernatant
was ultrafiltered using 3-kDa poliethersulfone membranes
with a filtering area of 0.5 m2. The feed flow rate and TMP
were kept constant at 1 L/min and 0.3-0.6 bar, respectively,
during the process. The final concentration factor of the
sample was 10 and the DF exchange factor 2. Ultrapure
water (MilliQ; Millipore, USA) was used as DF buffer.
Two different strategies were used at this point for the
purification of tagged and un-tagged pro-relaxin as de-
scribed in the figure (Fig. 3). The clarified supernatant
was concentrated by Tangential flow filtration (TFF)
using a Sartoflow system (Sartorius Stedim, Milan, Italy).
Polyethersuphone cassettes, having a cut-off of 3 kDa,
were used to reduce permeation of pro-relaxin (18 kDa)
and eventually relaxin (6 kDa). The filtering area used
was 0.07-0.1 m2 per liter of supernatant. During the
process, feed flow rate and transmembrane pressure
(TMP) were constant at 1 L/min and 0.3-0.6 bar, re-
spectively. The final concentration factor of the sample
was 13 ± 2 . Supernatant was diafiltered twice with ultra-
pure water to reduce sample conductivity before being
loaded onto an ion exchange chromatography.
Ion metal affinity chromatography (IMAC)
Ten ml of IMAC resin (Ni FF sepharose 6 fast flow, GE
Healthcare, Milan, Italy) were added for every liter of sam-
ple and incubated in batch at 300 rpm and 4 °C for 3 h.
The samples were centrifuged at 5000xg and 4 °C for
20 min (Avanti J26 XP, Beckman CoulterTM), and in order
to remove aspecifically bound proteins, the resin was
washed, for 15 min at 300 rpm, with a washing buffer con-
taining 20 mM imidazole, 500 mM sodium chloride,
pH 7.4 in the ratio of 1.5:1 with the resin. This step was
performed twice. The tagged protein was recovered by sus-
pending the resin in 500 mM imidazole, 500 mM sodium
chloride, pH 7.4 (1.5:1) at 300 rpm at 4 °C for 20 min [33].
Desalting
Fractions eluted from IMAC were loaded onto a desalt-
ing column (HiPrep 26/10 desalting, GE Healthcare,
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Milan, Italy). In order to reduce salt concentration and
remove imidazole, proteins were eluted with ultrapure
water (MilliQ; Millipore, USA) in 1.5 column volumes
(CV) at a flow rate of 1 ml/min. Eluted proteins were
detected at 214 and 280 nm and then separated by
reverse phase chromatography (RPC).
Reverse phase chromatography
A preparative reverse-phase column (RPC Resource
3 ml, GE Healthcare, Milan, Italy) previously equili-
brated with 95% buffer A (water, 0.1% trifluoracetic acid)
and 5% buffer B (acetonitrile, 0.1% trifluoroacetic acid)
was used for sample purification. A multistep gradient
(5 CV of 20% B, 5 CV of 30% B, 5 CV of 35% B, 5 CV of
45% B, 5 CV of 95% B) of buffer B at a flow rate of
1 mL/min was used to separate peptides into different
2 mL fractions. Eluted proteins were detected at 214 and
280 nm. All fractions collected were freeze dried (Epsi-
lon 2-6D, Martin Christ, Germany) and analysed by
western blotting and LC-MS.
Ion exchange chromatography (IEX)
The concentrated and diafiltered retentate containing
pro-relaxin and other host proteins was loaded with buf-
fer A (Sodium Acetate 20 mM, Sodium Chloride
5.0 mM, pH 5.5) on an anion exchange column (HiPrep
CM FF 16/10, GE Healthcare, Milan, Italy. Proteins
bound to the column were eluted applying a linear salt
gradient ranging from buffer A to buffer B in 5 column
volumes at flow rate of 1 ml/min and collected in 2 ml
fractions. Eluted proteins were detected at 214 and
280 nm. Salts were washed on 3KDa ultra filtering de-
vices (amicon,Millipore, Milan, Italy) lyophilised (Epsilon
2-6D, Martin Christ, Germany) and analysed by western
blotting. All fractions were further purified through a
reverse phase chromatography (RPC).
HPLC analyses
Fractions obtained throughout the purification processes
were analyzed by RP-HPLC. The system used was a Dio-
nex Ultimate 3000 (Thermofisher, Milan, Italy) equipped
of UV and RI detectors. The samples were loaded with
buffer A (water, 0.1% trifluoracetic acid) and applied to a
Vydac C8 4.6 x 150 mm, 5 μm (Grace, USA) column
temperature controlled at 25 °C C. Proteins bound to
the column were eluted applying a linear gradient from
5 to 40% of buffer B (acetonitrile, 0.1% trifluoroacetic
acid) in 50 min at flow rate of 0.5 ml/min. Eluted pro-
teins were detected at 280 nm.
RP-HPLC/IT-TOF mass spectrometry, LC-MS data
acquisition
LC-MS analyses were performed using an LC-MS/ESI-IT-
TOF instrument (Shimadzu Europe, Manchester, UK). All
the spectra were acquired using the LCMS Solution soft-
ware. Mass calibration and tuning were performed ac-
cording to the manufacturer’s recommendations.
Each sample of intact un-tagged and tagged pro-
relaxin H2 (0.4 μl injection volume), dissolved in aque-
ous solution, was injected onto the LC-MS at a flow rate
of 0.2 ml/min. The analyses were performed using an
analytical Vydac (Hesperia, CA) C18 column (2.1 x
100 mm, 5 μm), with water and acetonitrile (0.05% TFA)
as eluents. The proteins were eluted with a linear gradi-
ent of acetonitrile- 0.05% TFA, 15 - 65% over 8.5 min.
Mass spectra were acquired in positive scan mode over
m/z 600 - 2000 at 30 msec ion accumulation time. An
electrospray voltage of 1.60 kV and a nitrogen gas flow
of 1.5 L/min were employed.
Enzymatic digestion of the tagged protein was carried
out with 40 pmol of proteomic grade trypsin, in 25 mM
NH4HCO3 buffer, pH 7.5. Samples were incubated for
15 min with 10 mM DTT at 50 °C, and for 15 min with
20 mM IAA at room temperature prior to digestion,
then trypsin solution was added and samples were incu-
bated overnight at 37 °C. Peptide digest was pretreated
prior to LC-MS/MS analysis via solid phase extraction
tecnique (C18-Supelco) to remove detergents. Sample of
the peptide digest (2 μl injection volume), dissolved in
aqueous solution, was injected onto the LCMS at a flow
rate of 0.3 ml/min. The analyses were performed using
an analytical VydacProzap MS C18 column (2.1 x
20 mm, 1.5 μm), with water and acetonitrile (0.1%
formic acid) as eluents. The peptides were eluted with a
linear gradient of acetonitrile - 0.1% formic acid, 5 -
100% over 14 min. Mass spectra were acquired using
automatic acquisition mode, consisting in one MS scan
(mass range from 350 to 2000 m/z) followed by MS/MS
scans of the most abundant ions in each MS scan. MS/
MS spectra were measured automatically when the MS
signal surpassed the threshold of 50,000 counts, at
50 msec ion accumulation time. Each LC-MS/MS ana-
lysis was preceded and followed by blank runs to avoid
carryover contamination.
MS/MS data analysis
The acquired MS/MS spectra were transformed in Mas-
cot Generic format (.mgf) and used to query the NCBI
database 20151109 (76,068,736 sequences), with tax-
onomy restriction to Human (314,559 sequences), for
protein identification with an online open access version
of MASCOT software (www.matrixscience.com). Mascot
search parameters were: trypsin as enzyme; 3, as allowed
number of missed cleavages; carbamidomethylation of
cysteines as fixed modification; 20 ppm MS tolerance
and 0.6 Da MS/MS tolerance; peptide charge from +1 to
+3. Possible oxidation of methionine and the formation of
pyroglutamic acid from glutamine residues at the N-
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terminal position of peptides were considered as variable
modifications. Since NCBI Entry does not correspond
exactly to the expressed sequence, we manually searched
for N- and C-termini peptide fragments. We were able
to find the 1-8 and 159-164 peptides, further confirmed
by their MS/MS spectra.
Cell lysis
Five grams of wet biomass were suspended in 25 ml of
lysis buffer containing 50 mM sodium phosphate, 1 mM
EDTA and 5% glycerol. Glass beads were added to the
suspension and vortexed at 4 °C for 1 h. The super-
natant was treated with 50 U/ml of Dnase I for 40 min
at 4 °C and microfiltered on 0.45 μm filters.
Western blotting
Standard western blot protocols were used to monitor
the progress of the purification and qualitative evalu-
ation of the samples. The protein concentrations were
determined using the Bio-Rad protein assay reagent
(Bio-Rad Laboratories, Milan Italy). Whole cell extracts
and equal amounts of proteins were fractionated by
SDS-PAGE and transferred to a nitrocellulose mem-
brane using a transfer apparatus according to the manu-
facturer’s protocols (Bio-Rad Laboratories, Milan Italy).
After incubation with 5% w/v skimmed milk in Tris-
buffered saline (10 mM Tris, pH 8.0, 150 mM NaCl,
0.5% Tween 20) for 60 min, the membrane was washed
once with Tris-buffered saline (TBST) and incubated
with antibodies against Pro-relaxin Immunodiagnostik
(1:400), and Relaxin R&D (1:250) at room temperature
for 2 h. Membranes were washed three times for 10 min
and incubated with a 1:10000 dilution of horseradish
peroxidase-conjugated anti-mouse and anti-rat anti-
bodies for 1 h. Blots were washed with TBST three times
and developed with the ECL system (Amersham Biosci-
ences) according to the manufacturer’s protocols. The
protein concentration was quantified using a protein
assay kit from Bio Rad Laboratories (Hercules, CA,
USA) according to the manufacturer’s instructions.
Densitometric analysis of the film was performed using
a Model Universal Hood II imaging densitometer (Bio-
rad Laboratories) in trasmittance mode and analysed
using Bio-Rad discovery software. Bands were normal-
ised on the relaxin pure standard at different concentra-
tions (0.5-1-2-5 mg/ml)
Pro-relaxin in vitro bioassay
Recombinant pro-relaxin H2 was assayed for its ability
to induce cAMP production in a relaxin-expressing cell
line (THP-1) [34]. THP-1 cells (ATCC, LGC Standards
Italy) were grown in DMEM-F-12 containing 10% (v/v)
FBS, 1% (v/v) penicillin–streptomycin. The cells (5.0x104
cells/well) were cultured overnight in a 96-well culture
plate and were incubated at 37 °C for 30 min with
varying concentrations (range 10−6 to 10−9M) of relaxin
(recombinant-human-relaxin) used as reference and re-
combinant pro-relaxin H2 samples in the presence of
1 mM forskolin and 50 mM isobutylmethylxanthine
(IBMX). The plate was then briefly centrifuged, the
medium was removed and the cells were resuspended in
lysis buffer. cAMP levels in cell lysates were determined
using Amersham cAMP Biotrak enzyme immunoassay
system (VWR s.r.l, Italy). cAMP was evaluated in the
range of 12.5 to 3200 fmol/well generating a standard
curve by plotting the B/B0 percentage as a function of
the log cAMP concentration. The cAMP production was
normalised, for each concentration tested, on that ob-
tained with a positive control of human relaxin of
known concentration. The results are presented as aver-
age relative responses.
Each sample (fermentation supernatant or post-
purification) was analysed by performing three inde-
pendent experiments (3 assay plates) each in triplicate,
and results are indicated as mean ± S.D. for each sample.
Statistical significance was evaluated by T-student test.
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